Wrong. Here is the PR on the New Zealand study from July 1. http://investors.rockcreekpharmaceuticals.com/2015-07-01-Rock-Creek-Pharmaceuticals-Reports-Human-Proof-of-Principle-Study-of-Lead-Compound-Demonstrating-Inhibition-of-Inflammatory-Markers-In-White-Blood-Cells Here is the Aug 10 Q2 Results/Clinical update PR http://investors.rockcreekpharmaceuticals.com/2015-08-10-Rock-Creek-Pharmaceuticals-Announces-Targeting-of-Dermatological-Disease-Updated-Clinical-and-Regulatory-Strategy-and-Second-Quarter-Results Yes, this was delayed from Q2 projection, but let's at least be accurate.